Contact this trialFirst, we need to learn more about you.
Anti-tumor antibiotic
Camsirubicin for Soft Tissue Sarcoma
Recruiting2 awardsPhase 1
Seattle, Washington
This trial is testing a new cancer drug, camsirubicin, to see if it is safe and effective in treating advanced soft tissue sarcomas. The primary endpoint is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of camsirubicin. Secondary endpoints include safety, progression-free survival (PFS), time to progression (TTP), overall response rate (ORR), duration of response (DoR), overall survival (OS), and pharmacokinetics (PK).
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.